MX383507B - Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos. - Google Patents
Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos.Info
- Publication number
- MX383507B MX383507B MX2018007198A MX2018007198A MX383507B MX 383507 B MX383507 B MX 383507B MX 2018007198 A MX2018007198 A MX 2018007198A MX 2018007198 A MX2018007198 A MX 2018007198A MX 383507 B MX383507 B MX 383507B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- vectors
- immunodeficiency virus
- human immunodeficiency
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200138 | 2015-12-15 | ||
| EP16194124 | 2016-10-17 | ||
| PCT/EP2016/081159 WO2017102929A1 (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007198A MX2018007198A (es) | 2018-08-01 |
| MX383507B true MX383507B (es) | 2025-03-14 |
Family
ID=57737697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007198A MX383507B (es) | 2015-12-15 | 2016-12-15 | Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos. |
| MX2021006931A MX2021006931A (es) | 2015-12-15 | 2018-06-13 | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006931A MX2021006931A (es) | 2015-12-15 | 2018-06-13 | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10369214B2 (enExample) |
| EP (3) | EP3584252B1 (enExample) |
| JP (2) | JP6510149B2 (enExample) |
| KR (1) | KR20180086207A (enExample) |
| CN (2) | CN108368157B (enExample) |
| AU (2) | AU2016369326B2 (enExample) |
| BR (1) | BR112018011122A2 (enExample) |
| CA (1) | CA3008542C (enExample) |
| CY (2) | CY1122705T1 (enExample) |
| DK (2) | DK3584252T3 (enExample) |
| EA (1) | EA038974B1 (enExample) |
| ES (2) | ES2898271T3 (enExample) |
| HR (2) | HRP20191902T1 (enExample) |
| HU (2) | HUE055916T2 (enExample) |
| IL (1) | IL259942B2 (enExample) |
| LT (2) | LT3584252T (enExample) |
| MA (3) | MA44059B1 (enExample) |
| MD (2) | MD3390430T2 (enExample) |
| ME (1) | ME03545B (enExample) |
| MX (2) | MX383507B (enExample) |
| PH (1) | PH12018501047A1 (enExample) |
| PL (2) | PL3584252T3 (enExample) |
| PT (1) | PT3390430T (enExample) |
| RS (2) | RS62360B1 (enExample) |
| SG (2) | SG10202109457RA (enExample) |
| SI (2) | SI3390430T1 (enExample) |
| SM (2) | SMT202100623T1 (enExample) |
| TW (2) | TWI707039B (enExample) |
| WO (1) | WO2017102929A1 (enExample) |
| ZA (1) | ZA201803978B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2961024A1 (en) | 2014-09-26 | 2016-03-31 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| CA3008542C (en) | 2015-12-15 | 2020-06-02 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| EP3638302B1 (en) * | 2017-06-15 | 2024-03-13 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| MY200554A (en) | 2017-07-19 | 2024-01-03 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| CA3077340A1 (en) * | 2017-11-17 | 2019-05-23 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
| WO2020214203A1 (en) * | 2019-04-17 | 2020-10-22 | The Wistar Institute | Replication deficient adenoviral vectors for hiv vaccine applications |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| AU2020381082B2 (en) | 2019-11-07 | 2022-09-22 | Janssen Vaccines & Prevention B.V. | Protein purification |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2021249011A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| EP1816204B1 (en) | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (en) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4302513B2 (ja) * | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| EP1578766B1 (en) | 2002-12-03 | 2013-02-13 | University of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| EP2359851A3 (en) | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| EP1667631A4 (en) | 2003-09-15 | 2010-04-14 | Novartis Vaccines & Diagnostic | COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| EP1737885A2 (en) * | 2004-04-12 | 2007-01-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
| US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
| AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| ES2539010T3 (es) * | 2004-08-27 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007149491A2 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| HUE031411T2 (en) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | New Methods and Preparations |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| PT2358757T (pt) * | 2008-11-18 | 2018-12-04 | Beth Israel Deaconess Medical Ct Inc | Vacinas antivirais com imunogenicidade celular melhorada |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| CN105399833B (zh) | 2010-01-04 | 2019-09-06 | Kj 生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
| US8859257B2 (en) | 2010-01-28 | 2014-10-14 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
| EP2611465A4 (en) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | ANTIBODIES FOR NEUTRALIZING THE HUMAN IMMUNODICITY VIRUS (HIV) |
| CN103370411B (zh) | 2010-12-14 | 2016-05-04 | 美国卫生和人类服务部 | 腺病毒血清型26和血清型35线状病毒疫苗 |
| KR102007444B1 (ko) * | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| WO2013040766A1 (zh) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 可诱导针对hiv的广谱免疫应答的方法和疫苗 |
| WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
| CN105263506B (zh) | 2013-01-07 | 2018-03-09 | 贝丝以色列女执事医疗中心 | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| EP3052518B1 (en) * | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
| WO2015128421A1 (en) * | 2014-02-28 | 2015-09-03 | Crucell Holland B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| CA2961024A1 (en) | 2014-09-26 | 2016-03-31 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| ES2836432T3 (es) * | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Ensayos para sistemas de expresión recombinante |
| CA3008542C (en) | 2015-12-15 | 2020-06-02 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh not_active IP Right Cessation
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro not_active IP Right Cessation
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 SM SM20210623T patent/SMT202100623T1/it unknown
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/ko active Pending
- 2016-12-15 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 MX MX2018007198A patent/MX383507B/es unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh not_active IP Right Cessation
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro not_active IP Right Cessation
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 SM SM20190629T patent/SMT201900629T1/it unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/me unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en not_active Ceased
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja not_active Expired - Fee Related
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383507B (es) | Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos. | |
| CY1124254T1 (el) | Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας | |
| DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| CO2019014677A2 (es) | Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos | |
| MX2015010783A (es) | Composicion de vacuna. | |
| AR101814A1 (es) | Partícula de tipo virus flavivirus | |
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции | |
| MX2015010102A (es) | Vacuna de subunidades anti-mycoplasma spp. | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
| AR094810A1 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| MX394998B (es) | Virus de vacuna del sindrome respiratorio y reproductivo porcino. | |
| MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
| AR094846A1 (es) | Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento | |
| EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| AR105134A1 (es) | Vacunas contra la influenza con coincidencia antigénica | |
| EA201992167A1 (ru) | Вакцина |